Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24404156 | 0.95 | PDK2 (0.35) | PARP1EP300PDK2GAAHPGD | |
| SCHEMBL12424645 | 0.93 | PARP1 (0.35) | PARP1EP300PDK2GAAHPGD | |
| SCHEMBL25954033 | 0.89 | PARP1 (0.33) | PARP1EP300PDK2GAAHPGD | |
| SCHEMBL10292844 | 0.87 | AVPR1A (0.34) | PARP1EP300PDK2KMT2AMEN1 | |
| SCHEMBL13868664 | 0.87 | AVPR1A (0.34) | PARP1EP300PDK2KMT2AMEN1 | |
| SCHEMBL12424698 | 0.86 | PDK2 (0.38) | PARP1PDK2GAAKMT2AMEN1 | |
| SCHEMBL4572100 | 0.86 | PARP1 (0.31) | PARP1PDK2GAAHPGDKMT2A | |
| SCHEMBL4568725 | 0.86 | PARP1 (0.31) | PARP1PDK2GAAHPGDKMT2A | |
| SCHEMBL12424610 | 0.85 | EHMT2 (0.35) | PARP1EP300PDK2GAAHPGD | |
| SCHEMBL10293035 | 0.85 | PARP1 (0.35) | PARP1PDK2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7976739-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7976739-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2055698-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100230649-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100230649-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2055698-A1 | CHROMENE COMPOUND | Tokuyama Corporation (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100230649-A1 | CHROMENE COMPOUND | CCNT1, RB1, H1-0 | PARP1 1524/4885EP300 1803/4885PDK2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.